

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

MES-OV

RRID:CVCL_CZ92

Type: Cell Line

Proper Citation

RRID:CVCL_CZ92

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_CZ92

Proper Citation: RRID:CVCL_CZ92

Description: Cell line MES-OV is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian serous cystadenocarcinoma

Defining Citation: [PMID:12960427](#), [PMID:16382445](#)

Comments: Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MES-OV

Synonyms: MESOV

Cross References: ATCC:CRL-3272, cancercellines:CVCL_CZ92, DepMap:ACH-002486, GEO:GSM95445, Progenetix:CVCL_CZ92, Wikidata:Q54905245

ID: CVCL_CZ92

Record Creation Time: 20220427T220803+0000

Record Last Update: 20260905T181137+0000

Ratings and Alerts

No rating or validation information has been found for MES-OV.

No alerts have been found for MES-OV.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mortan LF, et al. (2026) Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer. *Cells*, 15(3).

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Evtimov VJ, et al. (2024) Targeting TAG-72 in cutaneous T cell lymphoma. *Heliyon*, 10(17), e36298.

Elayapillai S, et al. (2021) Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. *Gynecologic oncology*, 160(1), 302.

Ramraj SK, et al. (2020) Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. *International journal of cancer*, 147(4), 1086.